Angiotensin News and Research RSS Feed - Angiotensin News and Research

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.
Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. [More]
Expert creates new evidence-based guideline for managing sickle cell disease

Expert creates new evidence-based guideline for managing sickle cell disease

An expert panel has created a new evidence-based guideline for managing sickle cell disease (SCD), with a strong recommendation for the use of the drug hydroxyurea and transfusion therapy for many individuals with SCD, although high-quality evidence is limited, with few randomized clinical trials conducted for this disease, according to an article in the September 10 issue of JAMA. [More]
FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure). [More]
Novel polypill increases patient adherence to treatment following heart attack

Novel polypill increases patient adherence to treatment following heart attack

New research shows a novel polypill increases patient adherence to treatment following a myocardial infarction (MI) or heart attack, according to new study results reported at the European Society of Cardiology's ESC Congress 2014 in Barcelona, Spain. [More]
Investigational LCZ696 drug: A real breakthrough for patients with heart failure

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014. [More]
Heart failure is major public health burden in many LMICs

Heart failure is major public health burden in many LMICs

Heart failure is a major public health burden in many low- and middle-income countries (LMICs), with substantial variation in the presentation, causes, management, and outcomes of heart failure across different LMICs, according to a study published in this week's PLOS Medicine. [More]
Inadequate management common in young-onset Type 2 diabetes

Inadequate management common in young-onset Type 2 diabetes

Patients with young-onset Type 2 diabetes have worse metabolic control than those with late-onset disease, but they are less likely to receive organ-protective drugs, show data from the Joint Asia Diabetes Evaluation cohort. [More]
Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan. [More]
U.S. scientists fail to study possible role of innate variation in athletic performance

U.S. scientists fail to study possible role of innate variation in athletic performance

Compared to scientists working in other countries, U.S.-based scientists are underrepresented as authors of articles on the potential role of innate variation in athletic performance that are published in peer-reviewed science journals, according to Grand Valley State University researchers. [More]
Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

When the body receives an injury to the skin, a signal is sent to the brain, which generates a sensation of pain. [More]
FDA accepts Symplmed's Prestalia NDA for hypertension treatment

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA's guidance. [More]
New path may lead to powerful adjunctive novel therapy for PTSD treatment

New path may lead to powerful adjunctive novel therapy for PTSD treatment

There are currently only two FDA-approved medications for the treatment of posttraumatic stress disorder (PTSD) in the United States. Both of these medications are serotonin uptake inhibitors. Despite the availability of these medications, many people diagnosed with PTSD remain symptomatic, highlighting the need for new medications for PTSD treatment. [More]
Endocrine Society announces winners of Early Investigators Awards and FLARE Internship Awards

Endocrine Society announces winners of Early Investigators Awards and FLARE Internship Awards

The Endocrine Society is pleased to announce the recipients of the 2014 Early Investigators Awards and the Future Leaders Advancing Research in Endocrinology Internship Awards. [More]
Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. [More]
PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

The PARADIGM-HF trial has been stopped early for a benefit to patients that was overwhelmingly statistically significant. [More]
Intensive insulin treatment improves survival for diabetic heart attack patients

Intensive insulin treatment improves survival for diabetic heart attack patients

Long-term follow-up of the DIGAMI 1 trial – a landmark study of type 2 diabetes in Sweden – shows that intensive insulin treatment prolonged life by more than 2 years in patients with diabetes after a heart attack, compared with standard treatment for diabetes, reports Dr Viveca Ritsinger from the Unit of Cardiology of the Department of Medicine, Karolinska Institute, Stockholm, Sweden and colleagues in The Lancet Diabetes & Endocrinology. [More]
Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation. [More]
Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

Between 10 and 20 percent of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy. [More]

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia. [More]
Vitamin D receptor gene variant protects against male LUTS

Vitamin D receptor gene variant protects against male LUTS

An international research effort aimed at identifying the genetic basis of lower urinary tract symptoms has identified five candidate genes, one of which – encoding the vitamin D receptor – is consistently protective against these symptoms in men. [More]